VRDN Earnings Viridian Therapeutics, Inc.De
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–18 of 18
| Q3 2024 | 2024-09-30 | -2.98 | 2024-11-12 | 10-Q |
| Q2 2024 | 2024-06-30 | -1.82 | 2024-08-08 | 10-Q |
| Q1 2024 | 2024-03-31 | -0.79 | 2024-05-08 | 10-Q |
| FY 2023 | 2023-12-31 | -5.31 | 2024-02-27 | 10-K |
| Q3 2024 | 2023-09-30 | -3.97 | 2024-11-12 | 10-Q |
| Q2 2024 | 2023-06-30 | -2.88 | 2024-08-08 | 10-Q |
| Q1 2024 | 2023-03-31 | -1.61 | 2024-05-08 | 10-Q |
| FY 2023 | 2022-12-31 | -4.05 | 2024-02-27 | 10-K |
| Q3 2023 | 2022-09-30 | -2.88 | 2023-11-13 | 10-Q |
| Q2 2023 | 2022-06-30 | -2.05 | 2023-08-08 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.98 | 2023-05-10 | 10-Q |
| FY 2023 | 2021-12-31 | -6.66 | 2024-02-27 | 10-K |
| Q3 2022 | 2021-09-30 | -5.95 | 2022-11-14 | 10-Q |
| Q2 2022 | 2021-06-30 | -5.04 | 2022-08-15 | 10-Q |
| Q1 2022 | 2021-03-31 | -2.91 | 2022-05-13 | 10-Q |
| FY 2021 | 2020-12-31 | -31.13 | 2022-03-11 | 10-K |
| Q3 2021 | 2020-09-30 | -5.82 | 2021-11-05 | 10-Q |
| Q2 2021 | 2020-06-30 | -4.41 | 2021-08-12 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.